The agreement grants Bristol Myers Squibb access to incorporate Autolus' proprietary RQR8 safety switch into an initial set of selected cell therapy cancer programs.
Bristol Myers has an option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs.
Safety switches are designed to allow pharmacological agents to selectively eliminate cell therapy if a patient experiences severe adverse side effects from the treatment.
Autolus' proprietary RQR8 switch works by administration with the widely available and approved pharmaceutical antibody, rituximab.
Safety switches form part of Autolus' suite of cell programming modules designed to provide precise targeting, controlled, enhanced and sustained CAR T activity in a hostile tumor microenvironment.
Autolus will receive an upfront payment with the potential for near-term option exercise fees and development milestone payments.
In addition, Autolus would receive royalties on net sales of all Bristol Myers Squibb cell therapy products that incorporate the RQR8 safety switch.
Price Action: AUTL shares are up 17.43% at $2.56 on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.